Long-term course of Alzheimer disease in patients treated according to the Dutch dementia guideline at a memory clinic: A "real-life" study

Alzheimer Disease and Associated Disorders

Volumn 30, Issue 1, 2016, Pages 53-59

  Droogsma, Erika ^a   Van Asselt, Dieneke ^a   Van Steijn, Jolanda ^a   Diekhuis, Marjolein ^a   Veeger, Nic ^a,b   De Deyn, Peter P ^b,c  

^a MEDICAL CENTER LEEUWARDEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

" real life" setting; Alzheimer disease; Cholinesterase inhibitors; Community dwelling; Disease course; Memory clinic

Indexed keywords

GALANTAMINE; MEMANTINE; RIVASTIGMINE; CHOLINESTERASE INHIBITOR;

AGED; ALZHEIMER DISEASE; ARTICLE; CASE MANAGEMENT; CLOCK DRAWING TEST; DISEASE COURSE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NURSING HOME; PRACTICE GUIDELINE; PRIORITY JOURNAL; RESPITE CARE; RETROSPECTIVE STUDY; NETHERLANDS; NEUROPSYCHOLOGICAL TEST; PROTOCOL COMPLIANCE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DISEASE PROGRESSION; FEMALE; GUIDELINE ADHERENCE; HUMANS; LONGITUDINAL STUDIES; MALE; NETHERLANDS; NEUROPSYCHOLOGICAL TESTS; RETROSPECTIVE STUDIES;

EID: 84960940008     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/WAD.0000000000000090     Document Type: Article

References (36)

1. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol. 2011;7:137-152.
2. Burns A, Iliffe S. Alzheimer's disease. Clinical review. BMJ. 2009;338:467-471.
3. Schölzel-Dorenbos CJM, Draskovic I, Vernooij-Dassen MJ, et al. Quality of life and burden of spouses of Alzheimer disease patients. Alzheimer Dis Assoc Disord. 2009;23:171-177.
4. Rodda J, Carter J. Cholinesterase inhibitors and memantine for symptomatic treatment of dementia. BMJ. 2012;344:e2986.
5. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of NICE technology appraisal guidance 111).
6. NICE technology appraisal guidance 217.2011. Available at: http://www.nice.org.uk/TA217. Accessed February 21, 2015.
7. Kwaliteitsinstituut voor de gezondheidszorg CBO. Richtlijn diagnostiek en medicamenteuze behandeling van dementie. Alphen aan den Rijn: van Zuiden Communications. (Dutch guideline regarding the management of AD). 2005. Available at: http://www.artsennet.nl/Richtlijnen/Richtlijn/43407/Diagnostieken- medicamenteuze-behandeling-van-dementie.htm. Accessed February 21, 2015.
8. Birks J. Cholinesterase inhibitors for Alzheimer's disease (review). Cochrane Database Syst Rev. 2006;5:CD005593. Available at: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005593/abstract.
9. Fortin M, Dionne J, Pinho G, et al. Randomzied controlled trials: do they have external validity for patients with multiple comorbidities? Ann Fam Med. 2006;4:104-108.
10. Rothwell PM. External validity of randomised controlled trials: 'to whom do the results of this trial apply?' Lancet. 2005; 365:82-93.
11. Nederlandse Verengiging voor Klinische Geriatrie. Richtlijn Comprehensive Geriatric Assessment (Dutch guideline regarding the comprehensive geriatric assessment). 2011. Available at: http://www.nvkg.nl/uploads/Rg/a-/Rga-aH92aybEzpQ7M-ng8w/Definitieve-richtlijn-CGA.pdf. Accessed February 21, 2015.
12. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDSADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:189-198.
13. Salvi F, Miller MD, Grilli A, et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc. 2008;56:1926-1931.
14. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Pyschiatr Res. 1975;12:189-198.
15. Shulman KI, Gold DP, Cohen CA, et al. Clock-drawing and dementia in the community: a longitudinal study. Int J Geriatr Psychiatry. 1993;8:487-496.
16. Kemper P. The use of formal and informal home care by the disabled elderly. Health Serv Res. 1992;27:421-451.
17. Wattmo C, Paulsson E, Minthon L, et al. A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy. Clin Interv Aging. 2013;8:329-339.
18. Han L, Cole M, Bellavance F, et al. Tracking cognitive decline in Alzheimer's disease using the Mini-Mental State Examination: a meta-analysis. Int Psychogeriatr. 2000;12:231-247.
19. Persson CM, Wallin AK, Levander S, et al. Changes in cognitive domains during three years in patients with Alzheimer's disease treated with donepezil. BMC Neurol. 2009;9:7.
20. Gillette S, Andrieu S, Nourhashemi F, et al. Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement. 2011;7:579-592.
21. Vellas B, Hausner L, Frolich L, et al. Progression of Alzheimer disease in Europe: data from the European ICTUS study. Cur Alzheimer Res. 2012;9:902-912.
22. Wattmo C, Wallin AK, Londos E, et al. Predictors of longterm cognitive outcome in Alzheimer's disease. Alzheimers Res Ther. 2011;3:1-13.
23. Courtney C, Farrell D, Gray R, et al. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomized double-blind trial. Lancet. 2004;363:2105-2115.
24. Yaffe K, Fox P, Newcomer R, et al. Patient and caregiver characteristics and nursing home placement in patients with dementia. JAMA. 2002;287:2090-2097.
25. Smith GE, O'Brien PC, Ivnik RJ, et al. Prospectiv e analysis of risk factors for nursing home placement of dementia patients. Neurology. 2001;57:1467-1473.
26. Gaugler JE, Yu F, Krichbaum K, et al. Predictors of nursing home admission for persons with dementia. Med Care. 2009;47:191-198.
27. Mets T, De Deyn PP, Pals P, et al. COGNOS: care for people with cogntive dysfunction: a national observational study. Alzheimer Dis Assoc Disord. 2013;27:123-132.
28. Ientile L, De Pasquale R, Monacelli F, et al. Survival rate in patients affected by dementia followed by memory clinics (UVA) in Italy. J Alzheimers Dis. 2013;36:303-309.
29. Luppa M, Luck T, Brähler E, et al. Prediction of institutionalisation in dementia. A systematic review. Dement Geriatr Cogn Disord. 2008;26:65-78.
30. Wallin AK, Wattmo C, Minthon L. Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting. Neuropsychiatr Dis Treat. 2011;7:565-576.
31. Morris JC, Endland S, Clark D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease. Neurology. 1993;43:2457-2465.
32. Holmes C, Lovestone S. Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing. 2003;32:200-204.
33. Hager K, Baseman AS, Nye JS, et al. Effects of galantamine in a 2-year, randomized, placebo-controlled study in Alzheimer's disease. Neuropsychiatr Dis Treat. 2014;10:391-401.
34. Mohs R, Schmeidler J, Aryan M. Longitudinal studies of cognitive, functional and behavioural change in patients with Alzheimer's disease. Stat Med. 2000;19:1401-1409.
35. Holthoff VA, Ferris S, Ihl R, et al. Validation of the relevant outcome scale for Alzheimer's disease: a novel multidomain assessment for daily medical practice. Alzheimers Res Ther. 2011;3:27-37.
36. Ellis J. All inclusive benchmarking. J Nurs Manag. 2006;14: 377-383.